Serum-soluble PD-L1 may be a potential diagnostic biomarker in sepsis.
Acute Disease
Adolescent
Adult
Aged
Aged, 80 and over
Area Under Curve
B7-H1 Antigen
/ blood
Biomarkers
/ blood
CD3 Complex
/ immunology
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Female
Humans
Male
Middle Aged
Organ Dysfunction Scores
Pancreatitis
/ blood
Prognosis
ROC Curve
Sepsis
/ blood
Young Adult
diagnosis
immunity
inflammation
sPD-L1
sepsis
Journal
Scandinavian journal of immunology
ISSN: 1365-3083
Titre abrégé: Scand J Immunol
Pays: England
ID NLM: 0323767
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
22
04
2021
received:
13
12
2020
accepted:
28
04
2021
pubmed:
3
5
2021
medline:
25
6
2021
entrez:
2
5
2021
Statut:
ppublish
Résumé
To investigate whether serum-soluble PD-L1 (sPD-L1) is a potential biomarker for identifying sepsis. This study enrolled 64 septic patients, 29 patients with acute appendicitis, 33 patients with acute pancreatitis and 30 healthy volunteers. Sepsis was defined according to the Sepsis 3.0 criteria.[1] The associated clinical parameters were recorded, blood samples were collected on the first day of diagnosis, and serum sPD-L1 levels were measured using enzyme-linked immunosorbent assays. Compared with the control group, a significant increase in sPD-L1 levels was observed in patients with sepsis (n = 64). Increased sPD-L1 expression correlated strongly with increased clinical inflammatory values (CRP, PCT and WBC) and decreased immunological functional parameters (CD3
Substances chimiques
B7-H1 Antigen
0
Biomarkers
0
CD274 protein, human
0
CD3 Complex
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13049Subventions
Organisme : National Natural Science Foundation of China
ID : 81772040
Organisme : Project of Shanghai Municipal Commission of Health and Family Planning
ID : ZY(2018-2020)-FWTX-1108
Informations de copyright
© 2021 The Scandinavian Foundation for Immunology.
Références
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801-810.
Kempker JA, Martin GS. The changing epidemiology and definitions of sepsis. Clin Chest Med. 2016;37(2):165-179.
Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ. 2016;353:i1585.
Zambon M, Ceola M, Almeida-de-Castro R, Gullo A, Vincent JL. Implementation of the surviving sepsis campaign guidelines for severe sepsis and septic shock: we could go faster. J Crit Care. 2008;23(4):455-460.
Sands KE, Bates DW, Lanken PN,, et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA. 1997;278(3):234-240.
Vincent JL, Sakr Y, Sprung CL,, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34(2):344-353.
Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14(1):R15.
Pettila V, Hynninen M, Takkunen O, Kuusela P, Valtonen M. Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med. 2002;28(9):1220-1225.
Vincent JL, Donadello K, Schmit X. Biomarkers in the critically ill patient: C-reactive protein. Crit Care Clin. 2011;27(2):241-251.
O'Grady NP, Barie PS, Bartlett JG,, et al. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American college of critical care medicine and the infectious diseases society of America. Crit Care Med. 2008;36(4):1330-1349.
Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862-874.
Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat Rev Nephrol. 2018;14(2):121-137.
Patil NK, Guo Y, Luan L, Sherwood E. Targeting Immune cell checkpoints during sepsis. Int J Mol Sci. 2017;18(11):2413.
Nishimura H, Honjo T. PD-1: An inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 2001;22(5):265-268.
Guignant C, Lepape A, Huang X, et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care. 2011;15(2):R99.
Patera AC, Drewry AM, Chang K, Beiter ER, Osborne D, Hotchkiss RS. Frontline science: defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. J Leukoc Biol. 2016;100(6):1239-1254.
Chang K, Svabek C, Vazquez-Guillamet C, et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care. 2014;18(1):R3.
Shi MH, Xing YF, Zhang ZL, Huang JA, Chen YJ. Effect of soluble PD-L1 released by lung cancer cells in regulating the function of T lymphocytes. Zhonghua Zhong Liu Za Zhi. 2013;35(2):85-88.
Xing YF, Zhang ZL, Shi MH, Ma Y, Chen YJ. The level of soluble programmed death-1 in peripheral blood of patients with lung cancer and its clinical implications. Zhonghua Jie He He Hu Xi Za Zhi. 2012;35(2):102-106.
Jeannin P, Magistrelli G, Aubry JP, et al. Soluble CD86 is a costimulatory molecule for human T lymphocytes. Immunity. 2000;13(3):303-312.
Liu M, Zhang X, Chen H,, et al. Serum sPD-L1, Upregulated in sepsis, may reflect disease severity and clinical outcomes in septic patients. Scand J Immunol. 2017;85(1):66-72.
Zhao Y, Jia Y, Li C, Shao R, Fang Y. Predictive value of soluble programmed death-1 for severe sepsis and septic shock during the first week in an intensive care unit. Shock. 2019;51(3):289-297.
Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239-245.
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
Zhang Y, Zhou Y, Lou J, et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care. 2010;14(6):R220.
Patil NK, Bohannon JK, Sherwood ER. Immunotherapy: a promising approach to reverse sepsis-induced immunosuppression. Pharmacol Res. 2016;111:688-702.
Jubel JM, Barbati ZR, Burger C, Wirtz DC, Schildberg FA. The role of PD-1 in acute and chronic infection. Front Immunol. 2020;11:487.
Pan T, Zhou T, Li L, et al. Monocyte programmed death ligand-1 expression is an early marker for predicting infectious complications in acute pancreatitis. Crit Care. 2017;21(1):186.
Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434-452.
Pang P, Zhu Y, Jia B, et al. Increased serum levels of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients infected with Brucella. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016;32(12):1675-1678.
León-Flores A, Del Río Estrada PM, Álvarez-García LX, Piten-Isidro E, Reyes-Terán G. Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1(+) individuals. Immunol Lett. 2018;203:70-79.
Wang D, Zhou D, Du Q, et al. Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis C. Mol Med Rep. 2013;7(4):1197-1202.
Chen Y, Li M, Liu J,, et al. sPD-L1 Expression is associated with immunosuppression and infectious complications in patients with acute pancreatitis. Scand J Immunol. 2017;86(2):100-106.
Kofoed K, Andersen O, Kronborg G, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care. 2007;11(2):R38.
Hausfater P, Garric S, Ayed SB, Rosenheim M, Bernard M, Riou B. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin Infect Dis. 2002;34(7):895-901.
Gaïni S, Koldkjaer OG, Pedersen C, Pedersen SS. Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care. 2006;10(2):R53.
Chan YL, Tseng CP, Tsay PK, Chang SS, Chiu TF, Chen JC. Procalcitonin as a marker of bacterial infection in the emergency department: an observational study. Crit Care. 2004;8(1):R12-20.
Claeys R, Vinken S, Spapen H, et al. Plasma procalcitonin and C-reactive protein in acute septic shock: clinical and biological correlates. Crit Care Med. 2002;30(4):757-762.
Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med. 1998;24(8):888-889.